期刊
CANCERS
卷 15, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/cancers15164039
关键词
lung cancer; lung surgery; minimally invasive surgery; sublobar resection; video-assisted thoracoscopic surgery; robotic-assisted thoracoscopic surgery; enhanced recovery after surgery; immunotherapy; targeted therapy
类别
Lung cancer is a heterogeneous disease that presents significant challenges in diagnosis and treatment. Recent advances in surgery, perioperative management, and targeted therapy have revolutionized the treatment landscape for this disease, offering new hope for patients. This review aims to provide a comprehensive understanding of the latest surgical approaches in lung cancer and emphasizes the importance of integrating these modalities within a patient-centered and personalized treatment pathway.
Simple Summary Lung cancer is a heterogeneous disease, making it a complex and challenging condition to diagnose and treat effectively. However, recent advances have been made in surgery and perioperative management as well as in the emergence of new therapies (targeted therapy and immunotherapy). These novel treatment approaches have fundamentally altered the course of the disease, offering new hope and improved outcomes for patients. While surgery traditionally played a role mainly in the initial phases of lung cancer, its potential benefits are now being considered at various stages of the disease. The objective of this review is to provide a comprehensive description of the latest surgical approaches in lung cancer. We aim to highlight the importance of integrating these modalities within a patient-centered and personalized treatment pathway.Non-small cell lung cancer (NSCLC) is now described as an extremely heterogeneous disease in its clinical presentation, histology, molecular characteristics, and patient conditions. Over the past 20 years, the management of lung cancer has evolved with positive results. Immune checkpoint inhibitors have revolutionized the treatment landscape for NSCLC in both metastatic and locally advanced stages. The identification of molecular alterations in NSCLC has also allowed the development of targeted therapies, which provide better outcomes than chemotherapy in selected patients. However, patients usually develop acquired resistance to these treatments. On the other hand, thoracic surgery has progressed thanks to minimally invasive procedures, pre-habilitation and enhanced recovery after surgery. Moreover, within thoracic surgery, precision surgery considers the patient and his/her disease in their entirety to offer the best oncologic strategy. Surgeons support patients from pre-operative rehabilitation to surgery and beyond. They are involved in post-treatment follow-up and lung cancer recurrence. When conventional therapies are no longer effective, salvage surgery can be performed on selected patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据